KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pacira BioSciences (PCRX) Accumulated Depreciation & Amortization (2016 - 2026)

Pacira BioSciences has reported Accumulated Depreciation & Amortization over the past 16 years, most recently at $21.3 million for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization rose 0.77% year-over-year to $21.3 million; the TTM value through Mar 2026 reached $21.3 million, up 0.77%, while the annual FY2025 figure was $91.0 million, 15.53% up from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2026 was $21.3 million at Pacira BioSciences, down from $91.0 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $91.5 million in Q4 2022 and troughed at $18.4 million in Q1 2024.
  • A 5-year average of $49.9 million and a median of $48.5 million in 2025 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 319.54% in 2022 and later dropped 17.41% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $91.5 million in 2022, then dropped by 17.41% to $75.6 million in 2023, then increased by 4.25% to $78.8 million in 2024, then grew by 15.53% to $91.0 million in 2025, then crashed by 76.57% to $21.3 million in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for PCRX at $21.3 million in Q1 2026, $91.0 million in Q4 2025, and $69.7 million in Q3 2025.